Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Gangat N, et al. Among authors: elliott m. Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564. Online ahead of print. Am J Hematol. 2024. PMID: 39671248
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S, Baidoun F, Hreh M, Patnaik M, Hashmi S, Elliott M, Hogan W, Litzow M, Al-Kali A. Subari S, et al. Among authors: elliott m. Int J Hematol. 2016 Apr;103(4):409-15. doi: 10.1007/s12185-016-1935-0. Epub 2016 Jan 18. Int J Hematol. 2016. PMID: 26781617
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
Begna K, Al-Kali A, Elliott M, Foran J, Gangat N, Hogan W, Hook C, Leis J, Litzow M, Mesa R, Palmer J, Pardanani A, Patnaik M, Rivera C, Sproat L, Tibes R, Wolanskyj-Spinner A, Tefferi A. Begna K, et al. Among authors: elliott m. Am J Hematol. 2017 Nov;92(11):E626-E627. doi: 10.1002/ajh.24866. Epub 2017 Aug 17. Am J Hematol. 2017. PMID: 28730596 Free article. No abstract available.
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Gangat N, et al. Among authors: elliott ma. Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6. Am J Hematol. 2021. PMID: 33844862 Free PMC article.
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. Tefferi A, et al. Among authors: elliott ma. Am J Hematol. 2022 Sep;97(9):1127-1134. doi: 10.1002/ajh.26630. Epub 2022 Jun 30. Am J Hematol. 2022. PMID: 35702875 Free article.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Elliott MA, Mangaonkar A, Saliba A, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N. Karrar O, et al. Among authors: elliott ma. Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15. Am J Hematol. 2024. PMID: 38100217
3,223 results